Article Text

PDF
AB0468 Improved physical function, pain, and health related quality of life with certolizumab pegol in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the jrapid study
  1. H. Yamanaka1,
  2. K. Yamamoto2,
  3. T. Takeuchi3,
  4. N. Ishiguro4,
  5. Y. Tanaka5,
  6. K. Eguchi6,
  7. A. Watanabe7,
  8. H. Origasa8,
  9. T. Shoji9,
  10. Y. Sakamaki10,
  11. N. Miyasaka11,
  12. T. Koike12
  1. 1Tokyo Women’s Medical University
  2. 2The University of Tokyo
  3. 3Keio University, Tokyo
  4. 4Nagoya University, Aichi
  5. 5University of Occupational and Environmental Health, Fukuoka
  6. 6Sasebo City General Hospital, Nagasaki
  7. 7Tohoku University, Miyagi
  8. 8University of Toyama, Toyama
  9. 9Otsuka Pharmaceutical Co
  10. 10UCB Pharma
  11. 11Tokyo Medical and Dental University, Tokyo
  12. 12Hokkaido University, Hokkaido, Japan

Abstract

Background This study examined the efficacy of certolizumab pegol (CZP) + MTX in Japanese patients (pts) with active RA and an inadequate response to MTX.1

Objectives To assess the impact of CZP on physical function, pain and HRQoL in patients with concomitant MTX.

Methods In this 24-week (Wk), Phase II/III, multicenter, double-blind, randomised, placebo (PBO)-controlled, study, Japanese pts with active RA and an inadequate response to MTX were randomized (1:1:1:1) to CZP 100, 200, or 400mg +MTX, or PBO +MTX every 2 Wks. CZP pts received induction dosing with 200mg (100mg group) or 400mg (200 and 400mg groups) at Wks 0, 2, and 4. Pts who did not achieve an ACR20 response at Wks 12 and 14 were withdrawn from the study at Wk 16 and were eligible to enter an OLE study, as were pts completing the study. Primary efficacy end point was ACR20 response at Wk 12. Physical function was assessed with HAQ-DI and pain with VAS at each visit, and HRQoL with SF36 at Wks 12 and 24. ACR responses were assessed using NRI, and HAQ-DI, pain (VAS) and SF36 using LOCF.

Results A total of 316 pts were randomized. Demographic and baseline (BL) characteristics were similar between treatment groups: average values for RA disease duration ranged from 5.6 to 6.0 years, DAS28(ESR) from 6.19 to 6.46, HAQ-DI from 1.12 to 1.19, and MTX dose from 7.4 to 7.6mg/Wk across groups. ACR20 response at Wk 12 in CZP 100, 200, 400mg and PBO groups was 62.5%, 76.8%, 77.6%, and 28.6%, respectively (p<0.001 each CZP group vs PBO). As early as Wk 1, HAQ-DI was significantly improved in the CZP group vs PBO. HAQ-DI change from BL at Wk 1 was -0.24, -0.28, and -0.22 in the CZP groups vs -0.01 in the PBO group (p<0.001 each CZP group vs PBO), and at Wk 24 was -0.43, -0.55, and -0.57 in the CZP groups vs -0.18 in the PBO group (p<0.01 each CZP group vs PBO). Pain (VAS) was also significantly improved; change from BL at Wk 1 was -17.3, -16.6 and -14.8 in CZP groups vs -3.9 in PBO group (p<0.001 each CZP group vs PBO), and at Wk 24 was -26.9, -27.9 and -31.9 in CZP groups vs -10.6 in PBO group (p<0.001 each CZP group vs PBO). CZP 200mg and 400mg showed significantly greater improvements in the SF36 physical and mental components vs PBO at Wks 12 and 24. Changes in physical and mental components summary scores from BL at Wk 24 were 8.87, 10.17 and 11.36 in 100mg, 200mg and 400mg CZP groups vs 4.27 in PBO group (P<0.01 each CZP group vs PBO), and 3.19, 5.58 and 5.84 in CZP groups vs 1.24 in PBO group (P<0.01 for 200mg and 400mg CZP group vs PBO).

Conclusions Treatment with CZP + MTX resulted in a rapid and sustained reduction in RA signs and symptoms, and improved physical function, pain and HRQoL in Japanese RA patients with an inadequate response to MTX.

  1. Yamamoto H. et al. Arthritis Rheum;63(Suppl10);S474

Disclosure of Interest H. Yamanaka Grant/Research support from: Otsuka Pharmaceutical Co., Ltd, UCB Pharma, Consultant for: Otsuka Pharmaceutical Co., Ltd, UCB Pharma, K. Yamamoto Consultant for: Otsuka Pharmaceutical Co., Ltd, UCB Pharma, T. Takeuchi Consultant for: Otsuka Pharmaceutical Co., Ltd, UCB Pharma, N. Ishiguro Consultant for: Otsuka Pharmaceutical Co., Ltd, Y. Tanaka Consultant for: Otsuka Pharmaceutical Co., Ltd, K. Eguchi Consultant for: Otsuka Pharmaceutical Co., Ltd, A. Watanabe Consultant for: Otsuka Pharmaceutical Co., Ltd, H. Origasa Consultant for: Otsuka Pharmaceutical Co., Ltd, UCB Pharma, T. Shoji Employee of: Otsuka Pharmaceutical Co., Ltd, Y. Sakamaki Employee of: UCB Pharma, N. Miyasaka Consultant for: Otsuka Pharmaceutical Co., Ltd, T. Koike Consultant for: Otsuka Pharmaceutical Co., Ltd

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.